NCT06760364View on ClinicalTrials.gov

A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 25, 2024

Primary Completion Date

December 24, 2027

Study Completion Date

December 24, 2039

Conditions
Advanced Pancreatic Cancers
Interventions
DRUG

CHT102

CHT 102 : MSLN UCAR-T.

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors
collaborator

Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER